Skip to content
OpenCapital
Get started

BridgeBio Pharma BBIO Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)

Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies

Roivant Sciences logo
Roivant SciencesROIV
——

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K—
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%—

Returns & leverage

See full
Return on equity-216.8%—
Debt / equity2×—
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's total cash, cash equivalents, and restricted cash (inclusive).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BridgeBio Pharma's total cash, cash equivalents, and restricted cash (inclusive)?
BridgeBio Pharma (BBIO) reported total cash, cash equivalents, and restricted cash (inclusive) of $882.02M in Q1 2026.
How has BridgeBio Pharma's total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
BridgeBio Pharma's total cash, cash equivalents, and restricted cash (inclusive) increased by 62.5% year-over-year, from $542.74M to $882.02M.
What is the long-term trend for BridgeBio Pharma's total cash, cash equivalents, and restricted cash (inclusive)?
Over 2 years (2023 to 2025), BridgeBio Pharma's total cash, cash equivalents, and restricted cash (inclusive) has grown at a 20.4% compound annual growth rate (CAGR), from $394.73M to $572.14M.